Intelligence Feed event · Equity · 2026-09-12

    Eli Lilly Immunology Division Generates $2.6B in H1 2026 Revenue

    Question

    Eli Lilly Immunology Division Generates $2.6B in H1 2026 Revenue

    Direct answer

    Eli Lilly reported $2.6 billion in immunology revenue during the first half of 2026, representing a 9% year-over-year increase. The franchise is scaling newer products Ebglyss and Omvoh alongside core driver Taltz, integrating assets acquired through DICE, Morphic, and Merida to diversify beyond its core metabolic treatments.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Immunology Division Generates $2.6B in H1 2026 Revenue”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-division-generates-2-6b-in-h1-2026-revenue-5f7679

    EQUITY
    Eli Lilly Immunology Division Generates $2.6B in H1 2026 Revenue
    Eli Lilly reported $2.6 billion in immunology revenue during the first half of 2026, representing a 9% year-over-year increase. The franchise is scaling newer products Ebglyss and Omvoh alongside core driver Taltz, integrating assets acquired through DICE, Morphic, and Merida to diversify beyond its core metabolic treatments.
    LLYABBV
    Impact
    64
    SEP 12
    SIG
    90%
    LLYABBV
    Eli Lilly Immunology Division Generates $2.6B in H1 2026 Revenue
    Eli Lilly reported $2.6 billion in immunology revenue during the first half of 2026, representing a 9% year-over-year increase. The franchise is scaling newer products Ebglyss and Omvoh alongside core driver Taltz, integrating assets acquired through DICE, Morphic, and Merida to diversify beyond its core metabolic treatments.
    → Diversification into multi-billion-dollar immunology indications reduces Eli Lilly's valuation sensitivity to single-product GLP-1 revenue concentration.
    Impact
    Eli Lilly reported $2.6 billion in immunology revenue during the first half of 2026, representing a 9% year-over-year increase. The franchise is scaling newer products Ebglyss and Omvoh alongside core driver Taltz, integrating assets acquired through DICE, Morphic, and Merida to diversify beyond its core metabolic treatments.
    Affected
    LLYABBV
    Transmission
    Diversification into multi-billion-dollar immunology indications reduces Eli Lilly's valuation sensitivity to single-product GLP-1 revenue concentration.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYbiopharma revenue diversification beyond core incretin portfoliosUp1-3mImmunology revenue reached $2.6B (+9% YoY) in H1 2026.
    ABBVimmunology market share competition in dermatology and IBDWatch1-3mEbglyss and Omvoh compete directly in core AbbVie therapeutic areas.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month